Prime_therapeutics Coverage Criteria
Latest Prime_therapeutics coverage criteria updates25
- Coverage CriteriaClinical/Medical PolicyEff. 2026-11-01Resmetirom Prior Authorization and Quantity LimitsThis policy governs coverage of Rezdiffra (resmetirom) tablets for Boeing commercial members, including initial authorization, renewal, and quantity-limit exceptions. Coverage requires clinical criteria for noncirrhotic NASH/MASH with moderate-to-advanced fibrosis or another FDA-labeled indication, along with applicable safety, specialist, and documentation requirements.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-10-19PCSK9 Inhibitors Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Praluent, Repatha formulations, Lerochol, and Lipfendra for commercial plan members. It establishes covered indications, statin-use or intolerance requirements, preferred-agent rules, continuation criteria, and quantity-limit exceptions.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-09-15Proton Pump Inhibitors (PPIs) Quantity Limit Program SummaryThis policy governs quantity limits and exception approval criteria for selected proton pump inhibitors and related agents on the Boeing commercial formulary. It applies to requests for quantities exceeding the program limit, including requests supported by specified diagnoses or dosing circumstances.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-09-15Tarpeyo Prior Authorization with Quantity Limit Program SummaryCommercial coverage of Tarpeyo (budesonide delayed-release 4 mg capsules) for patients with primary immunoglobulin A nephropathy at risk for disease progression, subject to clinical criteria, specialist involvement or consultation, contraindication screening, and quantity-limit requirements.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-09-15Tezspire Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization, renewal, and quantity-limit approval for Tezspire (tezepelumab-ekko) 210 mg/1.91 mL subcutaneous auto-injector for Boeing commercial members. Coverage requires diagnosis-specific clinical criteria, appropriate concurrent therapy, specialist involvement, and avoidance of prohibited concomitant immunomodulatory agents.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-07-01Acute Migraine Prior Authorization with Quantity Limit Program SummaryPrior authorization and quantity-limit review for selected acute migraine therapies for Boeing commercial members, including initial and renewal criteria, prerequisite therapy requirements, quantity-limit exceptions, and 12-month approval durations.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-07-01Alpha-1 Proteinase Inhibitors Prior Authorization Program SummaryThis policy governs prior authorization for alpha-1 proteinase inhibitor products for Boeing commercial members, including initial and renewal coverage criteria for alpha-1 antitrypsin deficiency and steroid-refractory acute graft-versus-host disease.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-07-01Continuous Glucose Monitor Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity limits for continuous glucose monitor receivers, sensors, and transmitters for commercial members. Coverage applies to specified Dexcom and FreeStyle Libre products when clinical criteria and applicable quantity-limit requirements are met.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-06-15Tavneos Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Tavneos 10 mg capsules (avacopan) for Boeing commercial members. It establishes initial and renewal clinical criteria, quantity-limit exceptions, and a 12-month approval duration.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-01Krystexxa (pegloticase) Prior AuthorizationPrior authorization and medical-necessity criteria for Krystexxa (pegloticase) 8 mg/mL in adults with chronic gout who are refractory to conventional urate-lowering therapies and meet all stated clinical criteria.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-05-01Lysosomal Storage Disorders (LSD) Prior Authorization Program SummaryThis policy governs prior authorization and coverage criteria for enzyme-replacement therapies used to treat lysosomal storage disorders for Boeing commercial members, including requirements for initial and continuation therapy and non-preferred agents.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-04-01Brensocatib Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Brinsupri (brensocatib) 10 mg and 25 mg tablets for Boeing commercial members. It establishes initial and renewal clinical criteria, quantity-limit exception criteria, and 12-month approval periods.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-03-15Ketorolac Quantity Limit Program SummaryThis policy governs quantity-limit coverage for 10 mg ketorolac tromethamine tablets under the Boeing commercial formulary. It establishes the standard dispensing limit and clinical criteria for approving quantities that exceed the limit.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-03-15Topiramate ER Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity limits for Trokendi XR and Qudexy XR extended-release topiramate capsules for Boeing commercial members. Coverage requires qualifying clinical criteria, absence of FDA-labeled contraindications, and compliance with the applicable 30-day quantity limit unless an approved exception applies.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-02-15CFTR Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization, renewal, and quantity-limit review for CFTR modulator drugs for Boeing commercial members. It applies to providers requesting Alyftrek, Kalydeco, Orkambi, Symdeko, or Trikafta.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-02-15Daybue Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Daybue oral solution and Daybue stix oral powder packets for Boeing commercial members. Coverage is evaluated for patients with classic or typical Rett syndrome under the specified clinical and quantity-limit criteria.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2026-01-01Vasomotor Symptoms Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Lynkuet (elinzanetant 60 mg) and Veozah (fezolinetant 45 mg) for vasomotor symptoms, including initial and renewal therapy. It applies to commercial plan members and requires clinical criteria and, when applicable, justification for quantities above the program limit.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2025-12-15Elagolix and Relugolix Prior Authorization with Quantity Limit Program SummaryThis commercial Boeing policy governs prior authorization and quantity limits for Orilissa, Oriahnn, and Myfembree. Coverage applies to eligible premenopausal patients receiving therapy for endometriosis-associated pain or heavy menstrual bleeding associated with uterine fibroids, subject to clinical criteria, contraindication review, duration limits, and product-specific quantity limits.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2025-12-15Procysbi Prior Authorization Program SummaryThis policy governs prior authorization for Procysbi for commercial members. Approval requires an eligible indication, applicable age support, prior Cystagon history or qualifying intolerance or contraindication, specialist involvement, and no FDA-labeled contraindication to Procysbi.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyEff. 2025-12-15Zilbrysq Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Zilbrysq (zilucoplan) subcutaneous prefilled syringes for commercial plan members. It establishes initial and renewal clinical criteria, nonpreferred-agent requirements, prohibited combination therapy, contraindication screening, and dispensing limits.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyHarliku Prior Authorization with Quantity Limit Program SummaryThis policy governs coverage of Harliku 2 mg tablets for alkaptonuria under the Boeing commercial formulary, including prior authorization, prerequisite-agent, specialist, contraindication, renewal, and quantity-limit requirements.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyIL-5 Inhibitors Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization, renewal, and quantity-limit approval for Fasenra (benralizumab) and Nucala (mepolizumab) for covered eosinophilic and related inflammatory conditions. It applies to Boeing commercial members and requires clinical documentation, condition-specific maintenance therapy, specialist involvement, and review of concomitant immunomodulator use.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyMyalept (metreleptin) Prior Authorization Program SummaryThis policy governs prior authorization for Myalept 11.3 mg subcutaneous injection for Boeing commercial plan members. Coverage requires a qualifying indication, clinical documentation, specialist involvement or consultation, absence of contraindications and limitations of use, and dosing within FDA labeling.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicySGLT Inhibitors Quantity Limit Program SummaryThis program summary governs quantity limits for selected SGLT inhibitor products and SGLT inhibitor combination products on the Boeing commercial formulary. It defines standard quantities and clinical criteria for approving quantities that exceed the program limit.All prime_therapeutics updates
- Coverage CriteriaClinical/Medical PolicyViscosupplementation for Osteoarthritis Prior Authorization Program SummaryThis policy governs prior authorization for intra-articular viscosupplementation products used to treat knee osteoarthritis in commercial members. Coverage requires documented clinical criteria, failure of conservative therapies, appropriate treatment timing, absence of contraindications, and FDA-labeled dosing.All prime_therapeutics updates
Tool Description
Search Prime_therapeutics coverage criteria and medical necessity requirements across 21,000+ policies from 170+ payers.
Search a drug (“Wegovy”), a procedure (“knee replacement”), or a policy name, then filter by payer, specialty, policy type, or effective year. Or start from the largest publishers: UnitedHealthcare coverage criteria and Cigna coverage criteria.
Each result links the full policy page, which lists the clinical requirements, covered codes, and effective dates from the source document.
Pair a criteria search with the prior authorization lookup for approval requirements, the timely filing lookup for claim deadlines, the live policy updates feed for the newest payer publications, and payer profiles for contacts and coverage context.
FAQ
Coverage Criteria by Payer
Go deeper
Explore OpenPayer Data
Coverage policies are updated every day. Follow payer coverage policy updates in the live policy feed, or browse all CPT, HCPCS and DRG billing codes.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Prior Authorization LookupSearch payer prior authorization policies by drug, procedure, or policy name.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.